Adverum Biotechnologies, Inc. (ADVM) Revenue History
Annual and quarterly revenue from 2012 to present
ADVM Revenue Over Time (2012–2024)
ADVM Revenue Growth History
4 of 10 years with positive growth- FY2012 revenue growth
- N/A
- FY2013 revenue growth
- +1500.0%
- FY2014 revenue growth
- +19.2%
- FY2015 revenue growth
- +305.4%
- FY2016 revenue growth
- -37.3%
- FY2017 revenue growth
- +27.1%
- FY2018 revenue growth
- -12.8%
- FY2019 revenue growth
- -84.5%
- FY2020 revenue growth
- -100.0%
- FY2021 revenue growth
- N/A
- FY2022 revenue growth
- -100.0%
- FY2023 revenue growth
- N/A
- FY2024 revenue growth
- -72.2%
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2025 | $0 | -100.0% |
| Q2 2025 | $0 | — |
| Q1 2025 | $0 | — |
| Q4 2024 | $0 | — |
| Q3 2024 | $1.0M | — |
| Q2 2024 | $0 | — |
| Q1 2024 | $0 | -100.0% |
| Q4 2023 | $0 | — |
Multi-year avg. share of annual revenue by fiscal quarter
Revenue Breakdown (FY 2024)
ADVM's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
ADVM Revenue Analysis (2012–2024)
Current Revenue & Growth
As of June 22, 2026, Adverum Biotechnologies, Inc. (ADVM) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q3 2025) recorded $0 in revenue
Historical Growth Trajectory
ADVM's 5-year compound annual growth rate (CAGR) stands at +32.0%, indicating outstanding long-term growth trajectory. The 3-year CAGR of -48.9% is below the 5-year average, signalling a growth deceleration in recent years. Adverum Biotechnologies, Inc.'s highest annual revenue of $7.5 million was recorded in 2021.
Revenue by Segment
ADVM's revenue is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company has a focused business model while developing other growth vectors.
Peer Comparison
Compared to Healthcare sector peers — including OCGN (-1.3% YoY), EDIT (+8.0% YoY), and KRYS (+25.1% YoY) — ADVM has underperformed the peer group in revenue growth. Compare ADVM vs OCGN →
ADVM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ADVMCurrent | $0 | -100.0% | +32.0% | -13915.9% | |
 OCGN | $4M | -1.3% | +152.5% | -1425.7% | |
 EDIT | $41M | +8.0% | -14.9% | -245.2% | |
 KRYS | $389M | +25.1% | - | 41.5% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 BMRN | $3.2B | +9.9% | +11.6% | 16.6% |
ADVM Historical Revenue Data (2012–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $1.0M | -72.2% | $1.0M | 100.0% | $-139,159,000 | -13915.9% |
| 2023 | $3.6M | - | $3.6M | 100.0% | $-128,942,000 | -3581.7% |
| 2022 | $0 | -100.0% | $0 | - | $-157,135,000 | - |
| 2021 | $7.5M | - | $7.5M | 100.0% | $-146,122,000 | -1948.3% |
| 2020 | $0 | -100.0% | $-4,158,000 | - | $-117,950,000 | - |
| 2019 | $250K | -84.5% | $0 | - | $-68,545,000 | -27418.0% |
| 2018 | $1.6M | -12.8% | $0 | - | $-78,081,000 | -4843.7% |
| 2017 | $1.8M | +27.1% | $0 | - | $-58,847,000 | -3182.6% |
| 2016 | $1.5M | -37.3% | $0 | - | $-115,284,000 | -7923.3% |
| 2015 | $2.3M | +305.4% | $2.3M | 100.0% | $-47,823,000 | -2062.2% |
| 2014 | $572K | +19.2% | $572K | 100.0% | $-24,402,000 | -4266.1% |
| 2013 | $480K | +1500.0% | $480K | 100.0% | $-3,454,000 | -719.6% |
| 2012 | $30K | - | $30K | 100.0% | $-1,816,000 | -6053.3% |
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ADVM — Frequently Asked Questions
Quick answers to the most common questions about buying ADVM stock.
Is ADVM's revenue growth accelerating or slowing?
ADVM revenue is declining -100.0% year-over-year. TTM revenue fell to $0.00, contrasting with the 5-year CAGR of +32.0%. The reversal reflects either macro headwinds or company-specific challenges.
What is ADVM's revenue history from 2012 to 2026?
Adverum Biotechnologies, Inc. (ADVM) revenue history spans 2012 to 2026. TTM revenue as of 2026 is $0.00, growing at -100.0% YoY. The 5-year CAGR is +32.0%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is ADVM's long-term revenue growth rate (CAGR)?
Adverum Biotechnologies, Inc.'s 5-year revenue CAGR of +32.0% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -100.0% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for ADVM.
Why does ADVM's quarterly revenue fluctuate?
ADVM quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Adverum Biotechnologies, Inc.'s revenue data from 2012 to 2026 shows full historical quarterly detail on this page.
How is ADVM's revenue distributed by segment?
ADVM reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does ADVM's revenue compare to industry peers?
Adverum Biotechnologies, Inc. (ADVM) with TTM revenue of $0.00 and -100.0% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.